Julia C. Friend

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer.”.

Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5004

N/A

0DataRank · unranked

94 citations

Sandeep Gurram, Munjid Al Harthy, Eric A. Singer, Abhinav Sidana, Brian Shuch +14 more

A phase 2 study of bevacizumab, erlotinib, and atezolizumab in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) associated or sporadic papillary renal cell cancer (pRCC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps4604

N/A

0DataRank · unranked

2 citations

Elad Sharon, Cheryl Ann Pickett-Gies, Lisa Mac, Julia C. Friend, Erin B. Purcell +14 more